Efficient Synthesis of 3-Aminocyclobut-2-en-1-ones: Squaramide Surrogates as Potent VLA-4 Antagonists
摘要:
[GRAPHICS]A novel series of uniquely functionalized 3-aminocyclobut-2-en-1-ones has been prepared by facile condensation of a variety of cyclobuta-1,3-diones with a phenylalanine-derived primary amine. These systems subsequently lend themselves to substitution at C-2 by reaction with a variety of electrophilic reagents including N-halosuccinimides, sulfenyl chlorides, and Eschenmoser's salt. Compounds from this novel series are potent antagonists of VLA-4.
Efficient Synthesis of 3-Aminocyclobut-2-en-1-ones: Squaramide Surrogates as Potent VLA-4 Antagonists
摘要:
[GRAPHICS]A novel series of uniquely functionalized 3-aminocyclobut-2-en-1-ones has been prepared by facile condensation of a variety of cyclobuta-1,3-diones with a phenylalanine-derived primary amine. These systems subsequently lend themselves to substitution at C-2 by reaction with a variety of electrophilic reagents including N-halosuccinimides, sulfenyl chlorides, and Eschenmoser's salt. Compounds from this novel series are potent antagonists of VLA-4.
[EN] PROCESS FOR THE PREPARATION OF PHENYLALANINE ENAMIDE DERIVATIVES<br/>[FR] PROCEDE DE PREPARATION DE DERIVES DE PHENYLALANINE-ENAMIDE
申请人:CELLTECH R&D LTD
公开号:WO2004007428A1
公开(公告)日:2004-01-22
A process for the preparation of a class of phenylalanine enamide derivatives is described formula (1) wherein: Ar1 is an optionally substituted aromatic or heteroaromatic group; L2 is a linker group selected from -N(R4)- [where R4 is a hydrogen atom or an optionally substituted straight or branched C1-6alkyl group], -CON(R4)-, or -S(O)2N(R4)-; R1 is a carboxylic acid (-CO2H) or a derivative or biostere thereof; R2 is a hydrogen atom or a C1-6alkyl group; Rx, Ry and Rz which may be the same or different is each an atom or group -L1(Alk1)n(R3)v; and the salts, solvates, hydrates and N-oxides thereof; which comprises reacting a compound of formula (2): wherein: Qa is a group -N(R4)H; and the salts, solvates, hydrates and N-oxides thereof; with a compound Ar1W wherein W is a group selected from X1 (wherein X1 is a leaving atom or group), -COX2 (wherein X2 is a halogen atom or a -OH group) or -SO2 X3 (in which X3 is a halogen atom).
Phenylalanine enamide derivatives of formula (1) are described:
1
wherein
R
1
is a group Ar
1
L
2
Ar
2
Alk- in which:
Ar
1
is an optionally substituted aromatic or heteroaromatic group;
L
2
is a covalent bond or a linker atom or group;
Ar
2
is an optionally substituted arylene or heteroarylene group; and Alk is a chain —CH
2
—CH(R)13 , —CH═C(R)— or
2
in which
R is a carboxylic acid (—CO
2
H) or a derivative or biostere thereof;
X is an —O— or —S— atom or —N(R
2
)— group in which:
R
x
, R
y
and R
z
which may be the same or different is each a hydrogen atom or an optional substituent;
or R
z
is an atom or group as previously defined and R
x
and R
y
are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof.
The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.
Process for the preparation of phenylalanine enamide derivatives
申请人:——
公开号:US20040073033A1
公开(公告)日:2004-04-15
A process for the preparation of a class of phenylalanine enamide derivatives is described:
1
wherein:
Ar
1
is an optionally substituted aromatic or heteroaromatic group; L
2
is a linker group selected from —N(R
4
)—[where R
4
is a hydrogen atom or an optionally substituted straight or branched C
1-6
alkyl group], —CON(R
4
)—, or —S(O)
2
N(R
4
)—;
R
1
is a carboxylic acid (—CO
2
H) or a derivative or biostere thereof; R
2
is a hydrogen atom or a C
1-6
alkyl group; R
x
, R
y
and R
z
which may be the same or different is each an atom or group —L
1
(Alk
1
)
n
(R
3
)
v
;
and the salts, solvates, hydrates and N-oxides thereof;
which comprises reacting a compound of formula (2):
2
wherein:
Q
a
is a group —N(R
4
)H;
and the salts, solvates, hydrates and N-oxides thereof;
with a compound Ar
1
W wherein W is a group selected from X
1
(wherein X
1
is a leaving atom or group), —COX
2
(wherein X
2
is a halogen atom or a —OH group) or —SO
2
X
3
(in which X
3
is a halogen atom).
Compounds of formula (1) are described: in which X is an —O— or —S— atom or —N(R
2
)— group and R
1
is a group Ar
1
L
2
Ar
2
Alk- in which Ar
1
is an optionally substituted aromatic or heteroaromatic group, L
2
is a covalent bond or a linker atom or group, Ar
2
is an optionally substituted bicyclic heteroarylene group and Alk is a chain —CH
2
—CH(R)—, —CH═C(R)—, OR—CH(CH
2
R)— or which R is a carboxylic acid (—CO
2
H) or a derivative or biostere thereof. The compounds are selective inhibitors of alpha 4 integrins such as &agr;
4
&bgr;
1
and are of use in modulating cell adhesion for the prophylaxis or treatment of inflammatory diseases or disorders, such as rheumatoid arthritis, in which the extravasculation of leukocytes plays a role.
1
Phenylalanine enamide derivatives of formula (1) are described:
wherein
R
1
is a group Ar
1
L
2
Ar
2
Alk- in which:
Ar
1
is an optionally substituted aromatic or heteroaromatic group;
L
2
is a covalent bond or a linker atom or group;
Ar
2
is an optionally substituted arylene or heteroarylene group;
and Alk is a chain
in which R is a carboxylic acid (—CO
2
H) or a derivative or biostere thereof;
X is an —O— or —S— atom or —N(R
2
)— group in which:
R
x
, R
y
and R
z
which may be the same or different is each a hydrogen atom or an optional substituent;
or R
z
is an atom or group as previously defined and R
x
and R
y
are joined together to form an optionally substituted spiro linked cycloaliphatic or heterocycloaliphatic group; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders or disorders involving the inappropriate growth or migration of cells.